May 16, 2024 / 07:00AM GMT
Martin Amark - Xbrane Biopharma AB - Chief Executive Officer
Hello, everybody, and welcome to our webcast in relation to Q1 report 2024 for Xbrane Biopharma. I'm Martin Ãmark, CEO. And I have with me Anette Lindqvist, our CFO. We're going to talk about the development activities we had during the course of the quarter. And I think one thing we get back to is that we have successfully have been able to scale up the production process of our Opdivo biosimilar candidate Xbrane, which I think is a good achievement of the team. So this is our first product being expressed in mammalian cells and demonstrates the feasibility of our platform technology for mammalian cells have been successful in scale-up.
Okay. So just to recap our development portfolio, for those of you that have followed us for quite some time. We are dedicated solely to the development of biosimilars. And we have a portfolio of four biosimilar candidates. First one is Ximluci biosimilar to Lucentis launched in Europe, commercialized by our partner STADA and undergoing regulatory process with FDA for US approval. And recently, we
Q1 2024 Xbrane Biopharma AB Earnings Call Transcript
May 17, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers